anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The efficacy and safety of JARDIANCE for glycemic control were evaluated in a study of patients with type 2 diabetes mellitus with mild and moderate renal impairment (eGFR 30 to less than 90 mL/min/1.73 m2) [see Clinical Studies (14)]. In this study, 195 patients exposed to JARDIANCE had an eGFR between 60 and 90 mL/min/1.73 m2, 91 patients exposed to JARDIANCE had an eGFR between 45 and 60 mL/min/1.73 m2, and 97 patients exposed to JARDIANCE had an eGFR between 30 and 45 mL/min/1.73 m2. The glucose lowering benefit of JARDIANCE 25 mg decreased in patients with worsening renal function. The risks of renal impairment, volume depletion adverse reactions and urinary tract infection-related adverse reactions increased with worsening renal function [see Warnings and Precautions (5.2)]. Use of JARDIANCE for glycemic control in patients without established cardiovascular disease or cardiovascular risk factors is not recommended when eGFR is less than 30 mL/min/1.73 m2.

In a large cardiovascular outcomes study of patients with type 2 diabetes and established cardiovascular disease, there were 1819 patients with eGFR below 60 mL/min/1.73 m2. The cardiovascular death findings in this subgroup were consistent with the overall findings [see Clinical Studies (14)].

Studies of patients with heart failure [see Clinical Studies (14)] enrolled patients with eGFR equal to or above 20 mL/min/1.73 m2. No dose adjustment is recommended for these patients. There are insufficient data to support a dosing recommendation in patients with eGFR below 20 mL/min/1.73 m2.

Efficacy and safety studies with JARDIANCE did not enroll patients with an eGFR less than 20 mL/min/1.73 m2. JARDIANCE is contraindicated in patients on dialysis [see Contraindications (4)].
1. An agent for regulating iodine exchange or preventing iodine deficit conditions, comprising an iodinated organic compound, characterized in that the agent comprises an iodinated protein and/or an iodinated low-molecular component thereof, i.e. an iodinated polypeptide or peptide the structure of which includes at least one amino acid of the following group: tyrosine, phenylalanine, histidine, tryptophan. 2. The agent according to claim 1, characterized in that said iodinated protein is iodinated casein. 3. The agent according to claim 1, characterized in that said iodinated protein is iodinated lactoglobulin.
Background: Recent studies have shown that the baseline values of absolute aortic root diameter (ARD) and indexed diameter are associated with all-cause mortality and cardiovascular events in the general population, even in the absence of aneurysmal aortic disease. However, there is limited available data on the association between ARD and prognosis in end-stage renal disease (ESRD) patients receiving maintenance hemodialysis (MHD). Accordingly, the purpose of this study is to investigate the predictive value of ARD for all-cause mortality and cardiovascular events in this specific population.Methods: ARD was measured by echocardiography at the level of the sinuses of Valsalva at end diastole and indexed to body surface area (BSA). The primary endpoint was all-cause mortality. The secondary endpoint was major adverse cardiovascular events (MACE), including cardiovascular mortality, myocardial infarction and stroke. Cox proportional hazards models were conducted to evaluate the association between baseline ARD/BSA and clinical outcomes.Results: A total of 391 patients were included in this study. The primary endpoint occurred in 95 (24.3%) patients while the secondary endpoint occurred in 71 (18.2%) patients. Multivariate Cox regression analysis showed that ARD/BSA was an independent prognostic factor for all-cause mortality (HR, per 1-SD increase, 1.403; 95% CI, 1.118-1.761; p = 0.003) as well as MACE (HR, per 1-SD increase, 1.356; 95% CI, 1.037-1.772; p = 0.026).Conclusions: Our results show that ARD/BSA is predictive of all-cause mortality and MACE in MHD patients with ESRD and support the view that assessment of ARD/BSA may refine risk stratification and preventive strategies in this population.
Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Within 35-56 days after completion of therapy, patients with stable or responsive disease undergo surgery. Patients may continue RO4929097 for 28 days after surgery in the absence of disease progression or unacceptable toxicity.
On the day of surgery, the intervention group will receive 2 doses of colchicine 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
Rugby is a very popular sport in France, since it has more than 300,000 dismissed. The 2023 World Cup will take place in France, and in view of the enthusiasm that is created around the "XV de France" team, there will be a great number of new players. Yet there are many injuries in this sport, despite the adaptations of the French Rugby Federation. The injuries of these amateur players will handicap their performance within their club (an injured player will be injured more easily in the future) and have a impact on their personal and professional life. With this in mind, it would be desirable to have a predictive tool for possible wounds. For this, Agullo et al. had in the previous study "Reproducibility of the Functional Movement Screen (FMS) test in the amateur Rugby player" (ID-RCB: 2018-A03490-55) selected this tool already evaluated in the context of prediction injuries in other sports (hockey or American football). The FMS offers an overall assessment of the subject, based on seven so-called movements fundamentals, combining mobility and stability, making it possible to assess the deficiencies of the individual; a prevention plan will then be adapted to the subject.
OBJECTIVE: To evaluate the impact of high-intensity focused ultrasound (HIFU) ablation on the histopathological features of locally recurrent fibroids tissue.
METHODS: Patients who underwent transabdominal hysterectomy or myomectomy for uterine fibroids from January 1, 2021 to July 1, 2023 at a teaching hospital in China were enrolled in this prospective study. The patients who underwent surgery for local recurrence of uterine fibroids after HIFU ablation were categorized as the HIFU group, and patients who had not undergone HIFU ablation for uterine fibroids were the control group. Hematoxylin-eosin (HE) staining, Masson staining, and immunohistochemical staining were performed to analyze the counts of smooth muscle cells (SMCs), collagen content, microvascular count, and the expression levels of estrogen receptor (ER) and progesterone receptor (PR) in the fibroid tissue specimens.
RESULTS: The mean SMC counts in the HIFU and control groups were 337.68/field and 328.52/field respectively. The mean collagen content in the HIFU group and control group were 46.06% and 41.69% respectively. The mean microvessel counts in the HIFU group and control group were 13.66/field and 14.08/field respectively. The mean ER scores in the HIFU and control groups were 6.9 and 7.47 respectively, and the mean PR scores were 7.3 and 7.56 respectively. Overall, there were no significant differences in the SMC counts, collagen content, microvascular counts, and the ER and PR expression levels between the HIFU group and control group (p > 0.05).
CONCLUSIONS: HIFU ablation has no effect on the pathological characteristics of local recurrent fibroid tissue, and is an ideal non-invasive treatment option.
PURPOSE:To suppress the decomposition reaction of the titled compound useful as an external drug for dermatic diseases, cosmetics, etc., to eliminate the irritant smell of the compound, and to stabilize for a long period, by adding collagen and a decomposed collagen protein to an aqueous solution of urea. CONSTITUTION:Urea is stabilized by adding collagen and/or decomposed collagen protein (hereinafter called as collagen derivative) to an aqueous solution of urea. The amount of the urea derivative to be added for the stabilization of urea is <=1/10 and >=3pts.wt. per 1pt. of urea. Even a slight decomposition of urea can be detected by the pH increase. Although there is certain pH variation in urea added with gelatin, it is considerably low, and the composition is free from ammonia smell.
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk groups. Nevertheless, there remains heterogeneity with respect to relapse-free survival (RFS) within these genetic-risk groups. Our training set included 306 adults on Alliance for Clinical Trials in Oncology studies with de novo CN-AML aged < 60 years who achieved a complete remission and for whom centrally reviewed cytogenetics, RNA-sequencing, and gene mutation data from diagnostic samples were available (Alliance trial A152010). To overcome deficiencies of the Cox proportional hazards model when long-term survivors are present, we developed a penalized semi-parametric mixture cure model (MCM) to predict RFS where RNA-sequencing data comprised the predictor space. To validate model performance, we employed an independent test set from the German Acute Myeloid Leukemia Cooperative Group (AMLCG) consisting of 40 de novo CN-AML patients aged < 60 years who achieved a complete remission and had RNA-sequencing of their pre-treatment sample. For the training set, there was a significant non-zero cure fraction (p = 0.019) with 28.5% of patients estimated to be cured. Our MCM included 112 genes associated with cure, or long-term RFS, and 87 genes associated with latency, or shorter-term time-to-relapse. The area under the curve and C-statistic were respectively, 0.947 and 0.783 for our training set and 0.837 and 0.718 for our test set. We identified a novel, prognostically relevant molecular signature in CN-AML, which allows identification of patient subgroups independent of 2022 ELN genetic-risk groups.Trial registration Data from companion studies CALGB 8461, 9665 and 20202 (trials registered at www.clinicaltrials.gov as, respectively, NCT00048958, NCT00899223, and NCT00900224) were obtained from Alliance for Clinical Trials in Oncology under data sharing study A152010. Data from the AMLCG 2008 trial was registered at www.clinicaltrials.gov as NCT01382147.
Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) and PEHO-like syndromes are very rare infantile disorders characterized by profound intellectual disability, hypotonia, convulsions, optic, and progressive brain atrophy. Many causative genes for PEHO and PEHO-like syndromes have been identified including CCDC88A. So far, only five patients from two unrelated families with biallelic CCDC88A variants have been reported in the literature. Herein, we describe a new family from Egypt with a lethal epileptic encephalopathy. Our patient was the youngest child born to a highly consanguineous couple and had a family history of five deceased sibs with the same condition. She presented with postnatal microcephaly, poor visual responsiveness, and epilepsy. Her brain MRI showed abnormal cortical gyration with failure of opercularization of the insula, hypogenesis of corpus callosum, colpocephaly, reduced white matter, hypoplastic vermis, and brain stem. Whole exome sequencing identified a new homozygous frameshift variant in CCDC88A gene (c.1795_1798delACAA, p.Thr599ValfsTer4). Our study presents the third reported family with this extremely rare disorder. We also reviewed all described cases to better refine the phenotypic spectrum associated with biallelic loss of function variants in the CCDC88A gene.
PURPOSE: To protect the corneas without obscuring the vision of an operator at all and to simultaneously enable the washing the same by preparing a soln. contg. a specific concn. of hydroxypropyl methyl cellulose and polyethylene oxide in a physiologically equil. salt soln. CONSTITUTION: The soln. contg. about >=1% hydroxypropyl methyl cellulose and about >=100ppm polyethylene oxide in the physiologically equil. salt soln. is prepd. as a viscoelastic aq./corpus vitreum substitute for an eye operation. The substitute is used in a method for washing and protecting the cornea tissues during the eye operation. This method includes steps of coating the inner cornea with the physiological salt soln. contg. about 2% hydrxpyropyl methyl cellulose and about 100ppm polyethylene oxide and simultaneously, periodically wetting the outer cornea with the adaptable physiological salt soln. contg. about half the hydroxypropyl methyl cellulose and about twice the polyethylene oxide.
The hollow embolism microsphere is a microsphere which is prepared from a high polymer material and has a unique shape structure, and is suitable for transcatheter arterial embolization. The hollow embolism microsphere can enter channels with different sizes, and has good embolism effect on various target positions. The hollow microspheres are porous inside, have the drug loading performance, are easy to control the drug release after carrying the drugs, and have good treatment effect. The preparation of the hollow microsphere does not need any emulsifier or surfactant, the reaction condition is mild, and the process is simple. The obtained microspheres have uniform shape and controllable size, and can control embolization time. Can load various medicines including protein heat-sensitive medicines, and the medicine encapsulation rate can reach more than 70 percent.
PURPOSE:To provide a dentifrice useful to recognize the proper tooth-cleaning time and the cleaned state of the sordes on tooth easily with the naked eyes, by compounding conventional moist dentifrice or a toothpaste with a specific amount of an acidic solvent, mixing with an acidity indicator, and adding a fluorescent dye to the mixture. CONSTITUTION:An acidic solvent such as citric acid is added to a dentifrice at a molar concentration of 0.07-0.35M, 4-5.5pH and 10-50wt%. An acidity indicator such as chlorophenol red, bromothymol blue, neutral red, etc. is added to the mixture in an amount of 0.02-0.1%, and a fluorescent dye such as food red 3, carotin, chlorophyll, etc. is added thereto at a ratio of 0.01-2.0% to obtain the objective dentifrice. The dentifrice discolors after the proper tooth- cleaning time to enable the recognition of the right timing with naked eye, and the state of cleaned sordes on teeth can be detected easily by irradiating with a specific radiation to effect the emission of light.
All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
BACKGROUND: Osteosarcoma (OS) is a leading malignant tumor reported with high mortality and morbidity. Dysexpression of CircBBS9 has been reported to exhibit a critical functional role in various diseases. However, the underlying molecular mechanisms of CircBBS9 in osteosarcoma are poorly characterized.
METHODS: The present study aims to investigate the impacts of CircBBS9 on the progression of osteosarcoma.
RESULTS: The findings of the study demonstrated the up-regulated expression of CircBBS9 in osteosarcoma. The Actinomycin D and RNase R treatment experiments confirmed that circBBS9 is indeed a circRNA. In addition, the knockdown of circBBS9 negatively impacted the migration, proliferation and invasion of osteosarcoma cells. Further investigations illustrated that circBBS9 controlled miR-485-3p and miR-485-3p might directly interact with HMGB1. miR-485-3p had a negative regulatory role in HMGB1's gene expression. Through rescue assays, it was verified that CircBBS9 promoted osteosarcoma progression through the miR-485-3p/HMGB1 axis. Finally, circBBS9 knockdown attenuated the in-vivo growth of osteosarcoma.
CONCLUSIONS: Conclusively, our study is the first time to examine the possible functional mechanism and regulation roles of CircBBS9 in osteosarcoma. The findings explained that CircBBS9 promoted the malignant osteosarcoma's progression by sponging miR-485-3p/HMGB1 and proposed CircBBS9 as a prognostic biomarker and therapeutic candidate for osteosarcoma patients.
OBJECTIVE: To compare the differences in risk factors and etiological classification between cerebral infarction in young patients and elderly patients, and explore the correlation between cerebral infarction in young patients and white matter lesions (WMLs).
METHODS: Sixty young patients with cerebral infarction and 142 elderly patients with cerebral infarction were included. The distributions of risk factors such as hypertension, diabetes, heart disease, smoking status, alcohol consumption status, migraine status, and WMLs in the two groups were carefully investigated and statistically analyzed.
RESULTS: According to the univariate analysis, the proportions of males, obese patients, patients with migraine, and patients with obstructive sleep apnea-hypopnea syndrome (OSAHS) in the young group were significantly greater than those in the elderly group. Hypertension, heart disease, and hyperhomocysteinemia were significantly more common in the elderly group than in the young group. According to the TOAST classification, the incidence of stroke of undetermined etiology in the young group was greater than that in the elderly group, whereas the incidence of large-artery atherosclerosis (LAA) in the elderly group was greater than that in the young group. Binary logistic regression analysis revealed that male sex, migraine status, and obstructive sleep apnea-hypopnea syndrome were independently associated with cerebral infarction in young adults, whereas hypertension, heart disease, and hyperhomocysteinemia were independently related to cerebral infarction in elderly individuals. In addition, the incidence of WMLs in the migraine group of young cerebral infarction patients was significantly greater than that in the nonmigraine group.
CONCLUSION: Compared with those in elderly patients with cerebral infarction, the risk factors for cerebral infarction in young patients are relatively controllable. Furthermore, more methods are needed to determine the etiology of unexplained cerebral infarction in young patients. WMLs are thought to have a relatively high incidence in young patients with cerebral infarction and are significantly associated with migraine.
Lymphocytes which are toxic to cancer cells and specific for a glyco-related antigen (GRA) of such cells are made by sensitising leucocytes to a GRA. Particularly the GRA is a component of cancer cell membranes and combines with a lectin specifically at the galactose or N-acetylgalactosamine terminal gp. GRA are isolated from human cancer cells by complexing with a lectin e.g. groundnut or soya lectin for glactose specificity, or Dolictios agglutinin or Luma bean lactin for N-acetylgalactosamine. Both types of lectin can be used to recover a single antigen. Also new are pharmaceutical compsns. contg. sensitised lymphocytes or GRA. Sensitised cells destroy cancer cells carrying the corresponding GRA and are specific since GRA do not occur on normal cells. They can be used in prevention or treatment of cancer.
Overfeeding triggers homeostatic compensatory mechanisms that counteract weight gain. Here, we show that both lean and diet-induced obese (DIO) male mice exhibit a potent and prolonged inhibition of voluntary food intake following overfeeding-induced weight gain. We reveal that FGF21 is dispensable for this defense against weight gain. Targeted proteomics unveiled novel circulating factors linked to overfeeding, including the protease  legumain (LGMN). Administration of recombinant LGMN lowers body weight and food intake in DIO mice. The protection against weight gain is also associated with reduced vascularization in the hypothalamus and sustained reductions in the expression of the orexigenic neuropeptide genes, Npy and Agrp, suggesting a role for hypothalamic signaling in this homeostatic recovery from overfeeding. Overfeeding of melanocortin 4 receptor (MC4R) KO mice shows that these mice can suppress voluntary food intake and counteract the enforced weight gain, although their rate of weight recovery is impaired. Collectively, these findings demonstrate that the defense against overfeeding-induced weight gain remains intact in obesity and involves mechanisms independent of both FGF21 and MC4R.
A system may include a therapy device configured to deliver a therapy to a patient, a feature detector, and a feature selection controller. The therapy device may include sensing circuitry configured to sense a biological signal from the patient, and a closed-loop controller operably connected to the therapy device and the sensing circuitry. The controller may be configured to implement a feedback control algorithm to control the delivered therapy based on the sensed signal by controlling at least one therapy parameter. The feature detector may be configured to detect a plurality of available features of the biological signal. The feature selection controller may be configured to implement a feature selection algorithm to determine closed-loop sensed feature(s) from the plurality of available features. The feedback control algorithm may be configured to use the at least one closed-loop sensed feature to control the therapy parameter(s).
Regular physical activity benefits older adults physically and mentally. However, the availability and the evidence for physical activity programs that are safe and appropriate for home-bound older adults at risk for nursing home admission are limited. The current project aims to examine the effectiveness of a safe physical activity program, led by home care aides who regularly help hard-to-reach older home care clients with housekeeping and routine personal care services in the home. The primary aim is to test whether the safe physical activity program with a built-in motivational enhancement component, performed in a seated position, preserves the function and well-being of home care clients. The secondary aim is to understand for whom the program is efficacious, the extent to which the program can reach the target population, the extent to which participants drop out of the program, the extent to which program participants maintain the behavioral change introduced by the intervention, and what the program's cost-effectiveness is. Building on a pilot project that demonstrated the program's feasibility in a large home care program funded by the state and Medicaid, this randomized controlled trial will inform future expansion of the physical activity program into real-world home care settings.